| アブストラクト | Older patients represent a subpopulation of concern for immune checkpoint inhibitor (ICI) toxicity because of changes in the aging immune system and the potentially relevant clinical implications for their quality of life. Current evidence on ICI safety in older patients is conflicting. This study aimed to assess whether older patient age was a risk factor for increased reporting with ICIs as compared to other antineoplastic drugs in VigiBase, the World Health Organization database of suspected adverse drug reactions. Disproportionality analyses computing the reporting odds ratios (RORs) were performed by age subgroups (<18 years, 18-64 years, 65-74 years, 75-84 years and >/=85 years). There were not signals of disproportionate reporting with ICIs specifically detected in older patient age subgroups (>/=65 years), which were not present in the disproportionality analysis over the entire dataset. A signal of disproportionate reporting with ICIs emerged for eye disorders only in the age subgroup 18-64 years (ROR 1.13, 95% confidence interval 1.05-1.23). These findings showed that adverse event reporting with ICIs in older patients was comparable to that in the overall patient cohort and prompt for the further investigation of eye disorders with ICIs to elucidating risk factors and defining management strategies. |
|---|
| 組織名 | Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological;Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano,;Switzerland.;Unit of Pharmacology, Department of Medical and Surgical Sciences, University of;Bologna, 40126 Bologna, Italy.;Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500;Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Universita della Svizzera Italiana, 6900 Lugano,;Department of Clinical Pharmacology and Toxicology, University Hospital Zurich,;8091 Zurich, Switzerland. |
|---|
